Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 2
2020 3
2021 3
2022 5
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer.
Joanito I, Wirapati P, Zhao N, Nawaz Z, Yeo G, Lee F, Eng CLP, Macalinao DC, Kahraman M, Srinivasan H, Lakshmanan V, Verbandt S, Tsantoulis P, Gunn N, Venkatesh PN, Poh ZW, Nahar R, Oh HLJ, Loo JM, Chia S, Cheow LF, Cheruba E, Wong MT, Kua L, Chua C, Nguyen A, Golovan J, Gan A, Lim WJ, Guo YA, Yap CK, Tay B, Hong Y, Chong DQ, Chok AY, Park WY, Han S, Chang MH, Seow-En I, Fu C, Mathew R, Toh EL, Hong LZ, Skanderup AJ, DasGupta R, Ong CJ, Lim KH, Tan EKW, Koo SL, Leow WQ, Tejpar S, Prabhakar S, Tan IB. Joanito I, et al. Among authors: guo ya. Nat Genet. 2022 Jul;54(7):963-975. doi: 10.1038/s41588-022-01100-4. Epub 2022 Jun 30. Nat Genet. 2022. PMID: 35773407 Free PMC article.
Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities.
Ho SWT, Sheng T, Xing M, Ooi WF, Xu C, Sundar R, Huang KK, Li Z, Kumar V, Ramnarayanan K, Zhu F, Srivastava S, Isa ZFBA, Anene-Nzelu CG, Razavi-Mohseni M, Shigaki D, Ma H, Tan ALK, Ong X, Lee MH, Tay ST, Guo YA, Huang W, Li S, Beer MA, Foo RSY, Teh M, Skanderup AJ, Teh BT, Tan P. Ho SWT, et al. Among authors: guo ya. Gut. 2023 Feb;72(2):226-241. doi: 10.1136/gutjnl-2021-326483. Epub 2022 Jul 11. Gut. 2023. PMID: 35817555
Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities.
Xu C, Huang KK, Law JH, Chua JS, Sheng T, Flores NM, Pizzi MP, Okabe A, Tan ALK, Zhu F, Kumar V, Lu X, Benitez AM, Lian BSX, Ma H, Ho SWT, Ramnarayanan K, Anene-Nzelu CG, Razavi-Mohseni M, Abdul Ghani SAB, Tay ST, Ong X, Lee MH, Guo YA, Ashktorab H, Smoot D, Li S, Skanderup AJ, Beer MA, Foo RSY, Wong JSH, Sanghvi K, Yong WP, Sundar R, Kaneda A, Prabhakar S, Mazur PK, Ajani JA, Yeoh KG, So JB, Tan P; Singapore Gastric Cancer Consortium. Xu C, et al. Among authors: guo ya. Gut. 2023 Sep;72(9):1651-1663. doi: 10.1136/gutjnl-2022-328332. Epub 2023 Mar 14. Gut. 2023. PMID: 36918265
Pan-Cancer Analysis of Ligand-Receptor Cross-talk in the Tumor Microenvironment.
Ghoshdastider U, Rohatgi N, Mojtabavi Naeini M, Baruah P, Revkov E, Guo YA, Rizzetto S, Wong AML, Solai S, Nguyen TT, Yeong JPS, Iqbal J, Tan PH, Chowbay B, Dasgupta R, Skanderup AJ. Ghoshdastider U, et al. Among authors: guo ya. Cancer Res. 2021 Apr 1;81(7):1802-1812. doi: 10.1158/0008-5472.CAN-20-2352. Epub 2021 Feb 5. Cancer Res. 2021. PMID: 33547160
Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition.
Sundar R, Huang KK, Kumar V, Ramnarayanan K, Demircioglu D, Her Z, Ong X, Bin Adam Isa ZF, Xing M, Tan AL, Tai DWM, Choo SP, Zhai W, Lim JQ, Das Thakur M, Molinero L, Cha E, Fasso M, Niger M, Pietrantonio F, Lee J, Jeyasekharan AD, Qamra A, Patnala R, Fabritius A, De Simone M, Yeong J, Ng CCY, Rha SY, Narita Y, Muro K, Guo YA, Skanderup AJ, So JBY, Yong WP, Chen Q, Göke J, Tan P. Sundar R, et al. Among authors: guo ya. Gut. 2022 Jul;71(7):1277-1288. doi: 10.1136/gutjnl-2021-324420. Epub 2021 Aug 25. Gut. 2022. PMID: 34433583 Free PMC article.
A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC.
Lai GGY, Yeo JC, Jain A, Zhou S, Pang M, Alvarez JJS, Sim NL, Tan AC, Suteja L, Lim TW, Guo YA, Shen M, Saw SPL, Rohatgi N, Yeong JPS, Takano A, Lim KH, Gogna A, Too CW, Da Zhuang K, Tan WL, Kanesvaran R, Ng QS, Ang MK, Rajasekaran T, Wang L, Toh CK, Lim WT, Tam WL, Tan SH, Skanderup AMJ, Tan EH, Tan DSW. Lai GGY, et al. Among authors: guo ya. JTO Clin Res Rep. 2022 Sep 21;3(12):100416. doi: 10.1016/j.jtocrr.2022.100416. eCollection 2022 Dec. JTO Clin Res Rep. 2022. PMID: 36426287 Free PMC article.
Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer.
Xing M, Ooi WF, Tan J, Qamra A, Lee PH, Li Z, Xu C, Padmanabhan N, Lim JQ, Guo YA, Yao X, Amit M, Ng LM, Sheng T, Wang J, Huang KK, Anene-Nzelu CG, Ho SWT, Ray M, Ma L, Fazzi G, Lim KJ, Wijaya GC, Zhang S, Nandi T, Yan T, Chang MM, Das K, Isa ZFA, Wu J, Poon PSY, Lam YN, Lin JS, Tay ST, Lee MH, Tan ALK, Ong X, White K, Rozen SG, Beer M, Foo RSY, Grabsch HI, Skanderup AJ, Li S, Teh BT, Tan P. Xing M, et al. Among authors: guo ya. J Clin Invest. 2020 Jun 1;130(6):3005-3020. doi: 10.1172/JCI126726. J Clin Invest. 2020. PMID: 32364535 Free PMC article.
Integrative epigenomic and high-throughput functional enhancer profiling reveals determinants of enhancer heterogeneity in gastric cancer.
Sheng T, Ho SWT, Ooi WF, Xu C, Xing M, Padmanabhan N, Huang KK, Ma L, Ray M, Guo YA, Sim NL, Anene-Nzelu CG, Chang MM, Razavi-Mohseni M, Beer MA, Foo RSY, Sundar R, Chan YH, Tan ALK, Ong X, Skanderup AJ, White KP, Jha S, Tan P. Sheng T, et al. Among authors: guo ya. Genome Med. 2021 Oct 11;13(1):158. doi: 10.1186/s13073-021-00970-3. Genome Med. 2021. PMID: 34635154 Free PMC article.
16 results